What is Xenon Pharmaceuticals Operating Cash Flow per Share?
Xenon Pharmaceuticals's operating cash flow per share for the
three
months ended in Mar. 2024 was $-0.56.
Xenon Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.21.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -16.00% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -24.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Xenon Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:
XENE'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -107.5 Med: -12.1 Max: 47.6
Current: -16
During the past 13 years, Xenon Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 47.60% per year. The lowest was -107.50% per year. And the median was -12.10% per year.
XENE's 3-Year OCF Growth Rate is ranked worse than 71.5% of 1235
companies
in the Biotechnology industry
Industry Median: 3.3
vs XENE: -16.00
Xenon Pharmaceuticals Operating Cash Flow per Share Historical Data
The historical data trend for Xenon Pharmaceuticals's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Xenon Pharmaceuticals Operating Cash Flow per Share Chart
Competitive Comparison of Xenon Pharmaceuticals's Operating Cash Flow per Share
For the Biotechnology subindustry, Xenon Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenon Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Xenon Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.
Xenon Pharmaceuticals Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Xenon Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.21
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenon Pharmaceuticals Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Xenon Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Xenon Pharmaceuticals (Xenon Pharmaceuticals) Business Description
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XENE has been successfully added to your 